Mometasone furoate
Elocom cream contains the active substance mometasone furoate. Mometasone furoate is a synthetic corticosteroid with strong action; when used locally, it has anti-inflammatory, antipruritic, and vasoconstrictive effects.
Elocom cream is indicated for the relief of inflammatory and pruritic symptoms in corticosteroid-responsive skin diseases, such as psoriasis and atopic dermatitis.
Before starting to use Elocom, you should discuss it with your doctor or pharmacist.
If symptoms of irritation or allergy occur after using the medicine, you should contact your doctor immediately.
In case of infections, the doctor will use appropriate antibacterial or antifungal treatment. If there is no rapid and positive response to treatment, the use of the corticosteroid should be discontinued until the infections are cured.
Due to the increased risk of systemic side effects of corticosteroids, Elocom should be avoided on large areas of the body, under dressings, for a long time, and on the skin of the face and in skin folds, as well as in children. If it is necessary to apply the medicine to the face, treatment should not last more than 5 days.
Elocom, like other medicines containing corticosteroids, may change the appearance of some skin lesions, making it difficult for the doctor to make a proper diagnosis, and may also delay healing.
You should consult a doctor, even if the above warnings refer to situations that have occurred in the past.
If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.
No data available.
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this medicine.
The safety of using Elocom during pregnancy has not been established.
Elocom can be used during pregnancy only if, in the doctor's opinion, the benefit to the mother outweighs the potential risk to the mother and fetus. However, the medicine should not be used on large areas of the body or for a long time. Animal studies have shown that corticosteroids may harm the fetus.
It is not known whether topical corticosteroids are absorbed through the skin into the body to an extent that could pass into breast milk.
The use of Elocom by breastfeeding women is possible only if the doctor decides, after careful consideration of the risk of side effects in children versus the benefits of treatment for the mother. If the doctor considers long-term therapy necessary, breastfeeding should be discontinued.
Elocom does not affect the ability to drive or use machines.
This medicine should always be used as directed by your doctor. If you are unsure, you should consult your doctor or pharmacist.
Diseased areas of the skin are usually smeared with a thin layer of cream once a day.
If you feel that the effect of the medicine is too strong or too weak, you should consult your doctor.
Elocom should be used with caution in children over 2 years of age, although the safety and efficacy of Elocom have not been studied for more than 3 weeks.
There is not enough data on the use of the medicine in children under 2 years of age.
You should use the smallest effective dose of the medicine that allows for the relief of symptoms.
Long-term treatment with corticosteroids may affect the growth and development of children.
No cases of overdose have been reported so far.
Long-term local use of corticosteroids may lead to suppression of the hypothalamic-pituitary-adrenal axis and adrenal insufficiency.
In case of overdose, the doctor will use appropriate symptomatic treatment and supportive therapy. Acute symptoms of corticosteroid overdose are usually reversible. In case of chronic poisoning, the doctor will recommend gradual withdrawal of the medicine.
You should not use a double dose to make up for a missed dose.
Like all medicines, Elocom can cause side effects, although not everybody gets them.
The following side effects have been observed during the use of topical corticosteroids:
After using the medicine on a large area of skin for a long time, especially with occlusive dressings, absorption of the medicine into the general circulation has been observed.
The following side effects have been observed during the local use of corticosteroids:
dry skin, skin irritation, dermatitis, perioral dermatitis, skin maceration, sweat retention, and the appearance of widened small blood vessels (telangiectasia).
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C, 02-222 Warsaw
tel.: +48 22 49 21 301
fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not store above 25°C.
Shelf life after first opening the packaging – 4 weeks.
Do not use damaged or opened packaging.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Elocom is a cream.
Packaging of the medicine
An aluminum tube internally coated with epoxy resin, with a polyethylene screw cap, containing 30 g of cream, placed in a cardboard box.
To obtain more detailed information, you should contact the marketing authorization holder or the parallel importer.
Organon Salud, S.L.
Paseo de la Castellana, 77
28046 Madrid
Spain
Schering-Plough Labo N.V.
Industriepark, 30
B-2220 Heist-op-den-Berg
Belgium
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
CEFEA Sp. z o.o. Sp. komandytowa
ul. Działkowa 56
02-234 Warsaw
Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warsaw
SHIRAZ PRODUCTIONS Sp. z o.o.
ul. Tymiankowa 24/28
95-054 Ksawerów
CANPOLAND SPÓŁKA AKCYJNA
ul. Beskidzka 190
91-610 Łódź
Marketing authorization number in Spain, the country of export: 797894.7
Parallel import authorization number: 255/22
Date of approval of the leaflet: 21.06.2022
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.